- £508.50m
- £681.80m
- €1.65bn
- 39
- 65
- 38
- 42
Annual income statement for C&C, fiscal year end - February 29th, EUR millions except per share, conversion factor applied.
2020 February 29th | 2021 February 28th | 2022 February 28th | R2023 February 28th | 2024 February 29th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1,719 | 737 | 1,438 | 1,686 | 1,653 |
| Cost of Revenue | |||||
| Gross Profit | 437 | 168 | 332 | 395 | 381 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1,689 | 824 | 1,382 | 1,617 | 1,742 |
| Operating Profit | 30.7 | -86.9 | 56.5 | 68.9 | -89.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 11.6 | -121 | 45.7 | 52.2 | -112 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 9.1 | -105 | 37.1 | 40.3 | -114 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | 9.1 | -105 | 37.1 | 40.3 | -114 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 9.1 | -105 | 37.1 | 40.3 | -114 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.328 | -0.218 | 0.022 | 0.144 | 0.106 |
| Dividends per Share |